EC holds patent policy hearing to collect stakeholders' views:
This article was originally published in Clinica
A total of 360 people have already registered for the European Commission's public hearing, in Brussels July 12, on the future of EU patent policy. This is the second step of the public consultation launched in January this year, which is focusing on the structure of the patent system in Europe rather than issues of substantive patent law. There had been some 2,000 replies to the written consultation, and the intention is for these to be published. The Commission will prepare a report summarising the outcome of both the written submissions and the July hearing, and post this on its website. It will then decide on the operational consequences. For further details, see: http://europa.eu.int/comm/internal-market/indprop/patent/ consultation-en.htm
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.